Today's Rundown Featured Story | | | Thursday, July 5, 2018 Gilead Sciences is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib due in the next few weeks that could be an antidote for the biotech’s hepatitis C hangover. |
|
|
Top Stories Thursday, July 5, 2018 Nextbiotix has raised €7 million ($8 million) to develop a bacterial treatment for inflammatory bowel diseases. The series A round will support work to rebalance the gut microbiome through the delivery of Faecalibacterium prausnitzii, one of the most abundant species of bacteria in the gut. Thursday, July 5, 2018 Cellect Biotechnology and a group at Technische Universität Dresden have teamed up to explore the combination of their stem cell technologies. If Cellect deems the experiments a success, it will seek to form a stem cell product development agreement. Thursday, July 5, 2018 BioMarin has teamed up with a local senior center in San Rafael, California, to advance a development project that would turn an old environmental cleanup site downtown into new laboratory and office space, as well as provide affordable housing and an activities center for the elderly. Thursday, July 5, 2018 Scientists in the U.K. have created a switch that controls protein expression in cultured cells and mouse embryos and could one day be used in human gene therapies, the researchers believe. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. | 
